Frontlight ResearchEarly access
CompletedPhase 2
A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
Key facts
- Who runs it
- Innovent Biologics (Suzhou) Co. Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 84 people enrolled
- Started
- 10 Jul 2024
- Ended
- 9 Jan 2025
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Febuxostat
- IBI128
- Record updated
- 27 March 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Participants must be aged between 18 and 75 years old (inclusive, as of the time of signing the informed consent form), with no gender restrictions
- Body Mass Index (BMI) should fall within the range of 18.0 to 40.0 kg/m² (including both ends of the range)
- Subjects must meet the 2015 ACR/EULAR classification criteria for the diagnosis of gout (refer to Appendix 4)
- At the screening stage, subjects must have a blood uric acid level of ≥480 μmol/L
- Subjects must voluntarily sign the informed consent form and agree to strictly adhere to the requirements outlined in this protocol
Who cannot take part
- Previous allergy or intolerance to Febuxostat
- Subjects who have taken uric acid lowering medications within 2 weeks prior to screening
- Subjects who experienced an acute gout flare-up within 4 weeks prior to screening or immediately before the first dose administration
- History of allergy to any component of Tigulixostat
- Subjects with a history of xanthinuria
- Subjects considered to have secondary gout (elevated serum uric acid due to causes other than renal insufficiency)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid.
Read full original descriptionShow less
This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.
The 4 groups in the trial
- Febuxostat 40mgExisting treatment, for comparison
Tablets, Once a day (QD), Per oral
Treatment: Febuxostat
- IBI128 50mgTreatment being tested
Tablets, Once a day (QD), Per oral
Treatment: IBI128
- IBI128 200mgTreatment being tested
Tablets, Once a day (QD), Per oral
Treatment: IBI128
- IBI128 100mgTreatment being tested
Tablets, Once a day (QD), Per oral
Treatment: IBI128
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Open Label, Multicenter, Parallel-group, Positive-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
- Record updated
- 27 March 2025